NCCN Guidelines® Insights - Head and Neck Cancers, Version 2.2017

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations regarding the increase in human papillomavirus–associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

Target Audience

This activity is designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Additional information
Supporters: 

This activity is supported by educational grants from Astellas, AstraZeneca, Celldex Therapeutics, Clovis Oncology, Genomic Health, Inc., Kyowa Hakko Kirin, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, and NOVOCURE. This activity is supported by an independent educational grant from Merck Co., Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
06/10/2017
Course expires: 
06/10/2018
Cost:
$0.00

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

EDITOR:
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

JNCCN:
Kimberly Callan, MS, Senior Director, Professional and Patient Publications, NCCN, has disclosed that she has no relevant financial relationships.
Genevieve Hartzman, MA, Journal Production Specialist, NCCN, has disclosed that she has no relevant financial relationships.

CE PLANNERS:
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships. (Employed by NCCN until 2/17/17)
Karen Kanefield, Manager, Continuing Education Accreditation and Program Operations, has disclosed that she has no relevant financial relationships.
Kathy Smith, Manager, CE Grant Writing & Project Management, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Director, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
David Adelstein, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Maura L. Gillison, MD, PhD, Panel Member, has disclosed that she receives grant/research from Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, Merck & Co., Inc., and Kyowa Hakko Kirin Co., Ltd.; and she received consulting fees/honoraria from Amgen Inc., Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, Merck & Co., Inc., Celgene Corporation, and Eli Lilly and Company.
David G. Pfister, MD, Panel Chair, has disclosed that he received consulting fees/honoraria from Boehringer Ingelheim GmbH, and that he has received grant/research support from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Eli Lilly and Company, Exelixis Inc., Genentech, Inc., GlaxoSmithKline, MedImmune Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.
Sharon Spencer, MD, Panel Vice-Chair, has disclosed that she has no relevant financial relationships.
Douglas Adkins, MD, Panel Member, has disclosed that he has received grant/research support from Pfizer Inc., Celgene Corporation, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.
Barbara Burtness, MD, Panel Member, has disclosed that she has received grant/research support from Advaxis, Inc., Merck & Co., Inc., and Bristol-Myers Squibb Company; received consulting fees/honoraria from Amgen Inc., Debiopharm International S.A., Celgene Corporation, and AstraZeneca Pharmaceuticals LP; and served as a scientific advisor for Boehringer Ingelheim GmbH, MedImmune Inc., and VentiRx Pharmaceuticals, Inc.
A. Dimitrios Colevas, MD, Panel Member, has disclosed that he received consulting fees/honoraria and other financial benefit from Pfizer Inc., and that he received grant/research support from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Innate Pharma S.A., IRX Therapeutics, Inc., and Threshold Pharmaceuticals.
Robert L. Foote, MD, Panel Member, has disclosed that he received royalty income from Bionix, Elsevier, and UpToDate.
Robert I. Haddad, MD, Panel Member, has disclosed that he received grant/research support from Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca Pharmaceuticals LP, and Celgene Corporation; and that he received consulting fees/honoraria from Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca Pharmaceuticals LP, Pfizer Inc., Celgene Corporation, and Eisai Inc.
Antonio Jimeno, MD, PhD, Panel Member, has disclosed that he has served as a scientific advisor for AstraZeneca Pharmaceuticals LP.
William M. Lydiatt, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Bharat B. Mittal, MD, Panel Member, has disclosed that he has no relevant financial relationships.
John A. Ridge, MD, PhD, Panel Member, has disclosed that he has no relevant financial relationships.
Cristina P. Rodriguez, MD, Panel Member, has disclosed that she received grant/research support from Merck & Co., Inc.
Jatin P. Shah, MD, PhD, Panel Member, has disclosed that he served as a scientific advisor for and received consulting fees/honoraria from Proteocyte Diagnostics Inc.
Randal S. Weber, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Sue S. Yom, MD, PhD, Panel Member, has disclosed that she has served as a scientific advisor for Eli Lilly and Company; received royalty income from Springer and UpToDate;
received other financial benefit from Merck & Co., Inc.; and received grant/research support from Genentech, Inc., and BioMimetix Pharmaceutical, Inc.
Jennifer L. Burns, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.
Susan D. Darlow, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-006-H01-P

All clinicians completing this activity will be issued a certificate of participation.

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to the NCCN Guidelines for Head and Neck Cancers
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Head and Neck Cancers

Accreditation Period

Course opens: 
06/10/2017
Course expires: 
06/10/2018

Price

Cost:
$0.00

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing

Multidisciplinary Management of Head and Neck Cancer

This information was originally presented at the NCCN 2017 Oncology Fellows Program: New Horizons in Quality Cancer Care™ held on March 26, 2017.

The purpose of this program is to educate future oncology practitioners about the application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other evidence-based treatment principles in the management of significant cancer types and supportive care issues.

Target Audience

This educational program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.

Additional information
Supporters: 

This activity is supported by educational grants from: AstraZeneca; Pfizer; Prometheus Laboratories Inc.; supported by educational funding provided by Amgen; supported by an independent medical education grant from Bristol-Myers Squibb; and supported by an independent educational grant from TESARO. 

Course summary
Course opens: 
05/15/2017
Course expires: 
03/01/2018
Cost:
$0.00

David Pfister, MD
Memorial Sloan Kettering Cancer Center

Sharon Spencer, MD
University of Alabama at Birmingham Comprehensive Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support.

The faculty listed below discloses no relevant financial relationships:
Sharon Spencer, MD

The faculty listed below disclose the following relevant financial relationships:
David Pfister, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Bayer HealthCare: Grant/Research Support
Boehringer Ingelheim GmbH: Consulting Fees, Honoraria
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genentech, Inc.: Grant/Research Support
GlaxoSmithKline: Grant/Research Support
MedImmune Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support

The activity planning staff listed below has no relevant financial interests to disclose:
Kimberly Bayer; Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until February 7, 2017); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until February 3, 2017)

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Susan Darlow, PhD

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Continuing education credit and contact hours are not available for this learning activity.

Available Credit

Learning Objectives

Following this program, participants should be able to:

  • Evaluate the need for a multidisciplinary team in caring for patients with head and neck cancer
  • Assess the supportive care needs of patients undergoing treatment for head and neck cancer, such as nutrition and dental evaluation and management

Accreditation Period

Course opens: 
05/15/2017
Course expires: 
03/01/2018

Price

Cost:
$0.00

Required Hardware/software

To complete this activity, users will need:

Opportunities and Challenges: Human Papillomavirus and Cancer

This information was originally presented at the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ held in Orlando, Florida, from March 23 - 25, 2017.

Target Audience

This educational program is designed to meet the educational needs of medical, surgical, and radiation oncologists; nurses; physician assistants; pharmacists; pathologists; and other health care professionals who manage patients with cancer.

Additional information
Supporters: 

The activity is supported by educational grants from Ariad; Astellas and Medivation, Inc.; AstraZeneca; BTG International Inc.; Celgene Corporation; Celldex Therapeutics; Foundation Medicine; Genentech; Genomic Health, Inc.; Gilead Sciences, Medical Affairs; Lilly; Merrimack Pharmaceuticals, Inc.; Novartis; Pfizer; Prometheus Laboratories Inc.; Taiho Oncology; and Takeda Oncology.

This activity is supported by independent educational grants from AbbVie; Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte, and Merck Co., Inc.

This activity is supported by educational funding provided by Amgen.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.70 ANCC contact hours
  • 0.75 Participation
Course opens: 
05/15/2017
Course expires: 
03/01/2018
Cost:
$0.00

Christina S. Chu, MD
Fox Chase Cancer Center

David G. Pfister, MD
Memorial Sloan Kettering Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN Continuing Education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME's, ANCC's, and ACPE's Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME's Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below discloses no relevant financial relationships:
Christina S. Chu, MD

The faculty listed below discloses the following relevant financial relationships:
David G. Pfister, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Bayer HealthCare: Grant/Research Support
Boehringer Ingelheim GmbH: Consulting Fees, Honoraria
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genentech, Inc.: Grant/Research Support
GlaxoSmithKline: Grant/Research Support
MedImmune Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until 2/7/2017); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until 2/3/2017); Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Jennifer Burns, BS; Susan Darlow, PhD; Jillian Scavone, PhD

Definitions

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.75 hours of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.70 contact hours.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: 0836-0000-17-035-H01-P

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.70 ANCC contact hours
  • 0.75 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Recognize the association between HPV and genital and head and neck cancers.
  • Summarize the state of the evidence regarding the effect of HPV on treatment response and outcome.

Accreditation Period

Course opens: 
05/15/2017
Course expires: 
03/01/2018

Price

Cost:
$0.00

Required Hardware/software

To complete this activity, users will need:

Recorded Presentation from the 2015 NCCN Oncology Case Manager and Medical Director Program™ - Overview of Less Common and Complex Cancers (Part II) – Head and Neck, Esophageal, and Colorectal Cancers

The 2015 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of six webinars on the topics of melanoma, biomarkers, management of cancer in older patients with comorbidities, managing symptoms and reducing complications, and two sessions on less common and complex cancers. This educational series is designed to help case managers and medical directors that are interested in learning more about the current state of the art in oncology care manage patients with cancer based on evidence and according to the recommendations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

Target Audience

This educational program is designed to meet the educational needs of nurse case managers, nurses in other roles (i.e., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.

Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Astellas Scientific and Medical Affairs, Inc. and Medivation
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Merck

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.45 ANCC contact hours
  • 1.50 CCM clock hours
  • 1.50 Participation
Course opens: 
01/14/2016
Course expires: 
01/14/2017
Cost:
$0.00
Rating: 
4

David R. Byrd, MD
Seattle Cancer Care Alliance

Nikhil I. Khushalani, MD
Moffitt Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below have no relevant financial relationships to disclose:

David R. Byrd, MD

The faculty listed below have disclosed the following relevant financial relationships:

Nikhil I. Khushalani, MD
Castle Biosciences: Consulting Fees/Scientific Advisor
AstraZeneca: Consulting Fees/Scientific Advisor
*BMS: Grant/Research Support
*Merck: Grant/Research Support
*Pfizer: Consulting Fees/Scientific Advisor
*Tracon: Consulting Fees/Scientific Advisor
*Threshold: Consulting Fees/Scientific Advisor
Allos/Spectrum: Consulting Fees/Scientific Advisor
Roche: Consulting Fees/Scientific Advisor

*Research funding received by institution

NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Deborah Freedman-Cass, PhD; Miranda Hughes, PhD; Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Comprehensive Cancer Network designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release date: January 14, 2016
Expiration date: January 14, 2017

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.45 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Release date: January 14, 2016
Expiration date: January 14, 2017

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.5 clock hours.

Activity Code: I00018805
Approval Number: 150004726

To claim these CEs, log into your CE Center account at www.ccmcertification.org.

Release date: January 14, 2016
Expiration date: January 8, 2017

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.45 ANCC contact hours
  • 1.50 CCM clock hours
  • 1.50 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Summarize available treatment plans for patients based on tumor biology, current guideline recommendations, and recent clinical evidence
  • Describe the clinical circumstances requiring patients to receive treatment by a multidisciplinary team with sub-specialty expertise

Accreditation Period

Course opens: 
01/14/2016
Course expires: 
01/14/2017

Price

Cost:
$0.00

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing

2015 NCCN Oncology Case Manager and Medical Director Program™ - Overview of Less Common and Complex Cancers (Part II) – Head and Neck, Esophageal, and Colorectal Cancers

January 8, 2016

The 2015 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of six webinars on the topics of melanoma, biomarkers, management of cancer in older patients with comorbidities, managing symptoms and reducing complications, and two sessions on less common and complex cancers. This educational series is designed to help case managers and medical directors that are interested in learning more about the current state of the art in oncology care manage patients with cancer based on evidence and according to the recommendations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

Target Audience

This educational program is designed to meet the educational needs of nurse case managers, nurses in other roles (i.e., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.

Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Astellas Scientific and Medical Affairs, Inc. and Medivation
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Merck

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 CCM clock hours
  • 1.50 Participation
Course opens: 
01/08/2016
Course expires: 
04/15/2016
Event starts: 
01/08/2016 - 11:00am
Event ends: 
01/08/2016 - 12:30pm
Cost:
$0.00

David R. Byrd, MD
Seattle Cancer Care Alliance

Nikhil I. Khushalani, MD
Moffitt Cancer Center

This activity is approved for AMA PRA Category 1 Credit(s)™. This program has been pre-approved by the Commission for Case Manager Certification to provide continuing education credit to Certified Case Managers (CCMs) and nursing credits are provided as well. View complete accreditation information

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 CCM clock hours
  • 1.50 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Summarize available treatment plans for patients based on tumor biology, current guideline recommendations, and recent clinical evidence
  • Describe the clinical circumstances requiring patients to receive treatment by a multidisciplinary team with sub-specialty expertise

Accreditation Period

Course opens: 
01/08/2016
Course expires: 
04/15/2016

Price

Cost:
$0.00

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - HPV and Head & Neck Cancer

Join Barbara Burtness, MD and Zain Husain, MD as they present their multidisciplinary expertise on a range of cases pertaining to human papillomavirus (HPV) infection and head and neck (H&N) cancer.

HPV infection is a risk factor for the development of squamous cancers of the oropharynx, particularly cancers of the lingual and palatine tonsils, and base of the tongue. The overall incidence of HPV positive H&N cancers is increasing in the United States, while the incidence of HPV negative (primarily tobacco  and alcohol related) cancer is decreasing. It has not yet been shown whether HPV vaccination will decrease the incidence of HPV positive oropharyngeal cancer, although this appears to be a promising approach. Tumor HPV testing is recommended for cancers of the oropharynx, because prior HPV infection is related to the development of many oropharyngeal cancers. Recent data suggest that HPV-positive and HPV-negative H&N squamous cell carcinomas have different genetic alterations. New targeted and immune therapy options may be available in the future. Data are rapidly evolving in the area of HPV-associated H&N cancer, and clinicians need to be aware of the most recent recommendations to provide the best management for their patients with H&N cancer.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.75 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
07/08/2015
Course expires: 
07/08/2016
Cost:
$0.00

Barbara Burtness, MD
Yale Cancer Center/Smilow Cancer Hospital

Zain Husain, MD
Yale Cancer Center/Smilow Cancer Hospital

Available Credit

  • 0.75 Participation
  • 0.75 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Learning Objectives

Following this activity, participants should be able to:

  • Describe current treatment options for patients with squamous cancers of the oropharynx
  • Examine the recent evidence about the role of human papillomavirus (HPV) in head and neck cancer

Accreditation Period

Course opens: 
07/08/2015
Course expires: 
07/08/2016

Price

Cost:
$0.00

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • For Windows: JavaScript and cookies enabled, Active X enabled and unblocked for Microsoft Internet Explorer, Java 6.0 or above
  • For Mac: JavaScript and cookies enabled, Plug-ins enabled in Safari, Java 6.0 or above
  • Adobe Reader or other PDF reader software for certificate viewing/printing

NCCN Guidelines® Insights - Head and Neck Cancers, Version 1.2015

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Additional information
Supporters: 

Supported by an educational grant from Eisai; a contribution from Exelixis Inc.; educational grants from Bristol-Myers Squibb, Genentech BioOncology, Merck, Novartis Oncology, Novocure; and by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
07/09/2015
Course expires: 
07/09/2016
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to the NCCN Guidelines for Head and Neck Cancers
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Head and Neck Cancers

Accreditation Period

Course opens: 
07/09/2015
Course expires: 
07/09/2016

Price

Cost:
$0.00

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - HPV and Head & Neck Cancer

June 22, 2015

Join Barbara Burtness, MD and Zain Husain, MD as they present their multidisciplinary expertise on a range of cases pertaining to human papillomavirus (HPV) infection and head and neck (H&N) cancer.

HPV infection is a risk factor for the development of squamous cancers of the oropharynx, particularly cancers of the lingual and palatine tonsils, and base of the tongue. The overall incidence of HPV positive H&N cancers is increasing in the United States, while the incidence of HPV negative (primarily tobacco  and alcohol related) cancer is decreasing. It has not yet been shown whether HPV vaccination will decrease the incidence of HPV positive oropharyngeal cancer, although this appears to be a promising approach. Tumor HPV testing is recommended for cancers of the oropharynx, because prior HPV infection is related to the development of many oropharyngeal cancers. Recent data suggest that HPV-positive and HPV-negative H&N squamous cell carcinomas have different genetic alterations. New targeted and immune therapy options may be available in the future. Data are rapidly evolving in the area of HPV-associated H&N cancer, and clinicians need to be aware of the most recent recommendations to provide the best management for their patients with H&N cancer.

The NCCN Guidelines are a set of evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient---including general health, disease specifics, concomitant conditions, and current and previous therapies---when deciding how to apply appropriate standard of care.  This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
06/19/2015
Course expires: 
08/14/2015
Event starts: 
06/22/2015 - 1:30pm
Event ends: 
06/22/2015 - 2:30pm
Cost:
$0.00

Barbara Burtness, MD
Yale Cancer Center/Smilow Cancer Hospital

Zain Husain, MD
Yale Cancer Center/Smilow Cancer Hospital

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Learning Objectives

Following this activity, participants should be able to:

  • Describe current treatment options for patients with squamous cancers of the oropharynx
  • Examine the recent evidence about the role of human papillomavirus (HPV) in head and neck cancer

Accreditation Period

Course opens: 
06/19/2015
Course expires: 
08/14/2015

Price

Cost:
$0.00

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing

Emerging Targeted Therapies in the Management of Metastatic/Recurrent Head and Neck Cancer: Exploring the EGFR Pathways and the Potential Role of Biomarkers

March 14, 2014

Target Audience

This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Additional information
Supporters: 

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
03/14/2014
Course expires: 
05/14/2014
Event starts: 
03/14/2014 - 12:00pm
Event ends: 
03/14/2014 - 1:00pm
Cost:
$0.00
The Westin Diplomat
3555 South Ocean Drive
Hollywood, FL 33019
United States

Barbara Burtness, MD
Fox Chase Cancer Center

Robert I. Haddad, MD
Dana-Farber/Brigham and Women’s Cancer Center |
Massachusetts General Hospital Cancer Center

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Learning Objectives

Following this program, participants should be able to:

  • Evaluate data from recent clinical trials of EGFRs in head and neck cancer, including data on emerging agents
  • Review key principles of therapy selection covered by aspects of current available guidance for metastatic/recurrent head and neck cancer
  • Discuss the potential implications of biomarkers on treatment choices

Accreditation Period

Course opens: 
03/14/2014
Course expires: 
05/14/2014

Price

Cost:
$0.00

Implementing Routine Screening for Distress, the Sixth Vital Sign, for Patients With Head and Neck and Neurologic Cancers

This study examined the benefits of incorporating screening for distress as a routine part of care for patients with head and neck and neurologic cancers in a tertiary cancer center. Using a comparative 2-cohort pre-post implementation sequential design, consecutive outpatients with head and neck and neurologic cancers were recruited into 2 separate cohorts. Cohort 1 included patients attending clinics during April 2010, before the implementation of the screening program. The program was then implemented and patients completed the Screening for Distress Minimum Dataset (the Edmonton Symptom Assessment System [ESAS] and the Canadian Problem Checklist [CPC]) at each clinic visit. Cohort 2 included patients attending clinics during March 2011. Consenting patients completed screening and outcome measures (ESAS, CPC, and either the Functional Assessment of Cancer Illness Therapy – Brain  or the Functional Assessment of Cancer Illness Therapy – Head and Neck). A total of 146 patients (78 head and neck and 68 neurologic) provided data for Cohort 1, and 143 (81 head and neck and 62 neurologic) provided data for Cohort 2. Compared with Cohort 1, patients with neurologic cancers in Cohort 2 reported significantly higher scores on the Functional Assessment of Cancer Therapy: General total and emotional quality of life subscale; fewer high scores (≥4) on the ESAS breathlessness item; and fewer problems with fears/worries, frustration/anger, finding meaning in life, and worry about friends/family. Head and neck patients in Cohort 2 reported significantly higher emotional quality of life and fewer problems with eating and weight than those in Cohort 1. Although no definitive causal attributions can be made, patients exposed to routine screening for distress reported better well-being and fewer emotional, physical, and practical problems than historical controls.

Target Audience

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
10/25/2013
Course expires: 
10/25/2014
Cost:
$0.00
Barry D. Bultz, PhD
Department of Psychosocial Resources, Tom Baker Cancer Centre
Department of Oncology, University of Calgary
Calgary, Alberta, Canada
Lisa Shirt
Department of Oncology, Tom Baker Cancer Center
University of Calgary
Calgary, Alberta, Canada
Amy Waller
Department of Psychosocial Resources, Tom Baker Cancer Centre
Department of Oncology, University of Calgary
Calgary, Alberta, Canada
Scott Blanchard
Department of Oncology, University of Calgary
Department of Oncology, Tom Baker Cancer Center
Calgary, Alberta, Canada
Paula Jones
Department of Psychosocial Resources, Tom Baker Cancer Centre
University of Calgary
Calgary, Alberta, Canada
Harold Lau
Department of Oncology, Tom Baker Cancer Center
University of Calgary
Calgary, Alberta, Canada
Johan Halland
Department of Psychosocial Resources, Tom Baker Cancer Centre
University of Calgary
Calgary, Alberta, Canada
Jacob Easaw
Department of Oncology, Tom Baker Cancer Center
University of Calgary
Calgary, Alberta, Canada
Jodi L. Cullum
Research and Evaluation Unit, Alberta Health Services
University of Calgary
Calgary, Alberta, Canada
Konrad Fassbender
Department of Oncology, Division of Palliative Care Medicine
University of Alberta
Edmonton, Alberta, Canada
Shannon Groff
Department of Psychosocial Resources, Tom Baker Cancer Centre
University of Calgary
Calgary, Alberta, Canada
Linda Carlson
Department of Psychosocial Resources, Tom Baker Cancer Centre
University of Calgary
Calgary, Alberta, Canada
Catriona Leckie
Department of Oncology, Tom Baker Cancer Center
University of Calgary
Calgary, Alberta, Canada

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the benefits that implementing a routine distress screening program had on patient-reported outcomes
  • Describe strategies to successfully implement screening for distress and ensure that services are provided to patients in response to concerns

Accreditation Period

Course opens: 
10/25/2013
Course expires: 
10/25/2014

Price

Cost:
$0.00

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing

Pages

Subscribe to RSS - Head and Neck Cancers